PAREXEL Academy Adds Programs for Students
Three new academic programs have been added to the PAREXEL Academy which span the globe and are designed to prepare students for careers in the biopharmaceutical industry.
Three new academic programs have been added to the PAREXEL Academy which span the globe and are designed to prepare students for careers in the biopharmaceutical industry:
·Bachelor of Science Degree in Clinical Research – Offered in partnership with the Medical School Berlin, in Berlin, Germany, the degree program features courses specific to clinical research. Courses range from ethics in health and medicine to conducting clinical trials. Several courses are taught by PAREXEL experts.
·Postgraduate Certificate in Clinical Trial Management – In cooperation with Salem State University in Salem, Massachusetts, the postgraduate certificate program features a broad-based curriculum in various components of the full life cycle of drug development.
·Joint Program for Clinical Research and Clinical Trial Management – In collaboration with Kyoto Pharmaceutical University in Kyoto, Japan, the joint program provides fifth grade undergraduate students an introductory, seven-week course in clinical research and clinical trial management.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
